# A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine

> **NCT05445440** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 30 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Leucovorin
- **DRUG:** BMS-986371
- **DRUG:** Sulfasalazine

## Key facts

- **NCT ID:** NCT05445440
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-06
- **Primary completion:** 2022-11-17
- **Final completion:** 2022-11-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445440, "A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05445440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*